WAVE LIFE SCIENCES LTD. Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-06-30 was $10.73M, a 73.22% increase year-over-year.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2026-03-31 was $9.06M, a 82.98% increase year-over-year.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-09-30 was $6.47M, a 83.29% increase year-over-year.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for the quarter ending 2025-06-30 was $6.20M, a 77.79% increase year-over-year.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2025 was $24.97M, a 90.04% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2024 was $13.14M, a 34.16% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2023 was $9.79M, a 43.03% decline from fiscal 2022.
- WAVE LIFE SCIENCES LTD. shares issued, value, share-based payment arrangement, before forfeiture for fiscal 2022 was $17.19M, a 4.80% increase from fiscal 2021.
| Period end | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 3 month | Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture 12 month |
|---|---|---|
| 2026-06-30 | $10.73M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $9.06M 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $24.97M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $6.47M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $6.20M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $4.95M 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $13.14M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $3.53M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $3.48M 10-Q · filed 2025-11-10 | |
| 2024-03-31 | $2.88M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $9.79M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $2.28M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $2.41M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $2.75M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $17.19M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $3.37M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $6.95M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $3.97M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $16.41M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $5.90M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $2.72M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $4.06M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $14.30M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $3.28M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $3.79M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $4.00M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $19.51M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $5.02M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $5.16M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $4.34M 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $15.60M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $3.61M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $3.54M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $4.43M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $12.14M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $6.85M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $814.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $4.02M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |